adapt trial: endocrine ribociclib vs. chemotherapy in hr /her2- early breast cancer
Published 7 months ago • 275 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
1:39
frontline endocrine therapies and ribociclib in early stage hr her2- breast cancer
-
0:36
maintenance w/ et ribociclib after 1l chemotherapy in hr /her2- metastatic breast cancer
-
4:02
assessment of short preoperative endocrine therapy in the adapt and adaptcycle trials
-
2:46
right choice: ribociclib et vs combo chemo in aggressive hr /her2− advanced breast cancer
-
3:11
a correlative analysis of coralleen: preoperative ribociclib letrozole vs chemo in hr /her2- bc
-
1:26
rxponder: chemotherapy and endocrine therapy in hr /her2- breast cancer
-
2:43
adaptcycle: adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus che...
-
2:00
ribociclib in early breast cancer | nejm
-
2:23
natalee: ribociclib nsai as adjuvant treatment in patients with hr /her2− early breast cancer
-
3:08
adding ribociclib to endocrine therapy shows an improvement in invasive dfs in hr /her2 bc patients
-
2:10
monarche: adjuvant abemaciclib endocrine therapy in patients with hr , her2- high-risk ebc
-
1:48
natalee and monarche: ribociclib and abemaciclib in hr /her2- breast cancer
-
0:59
ribociclib in adjuvant hr breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
1:20
phase ii adapt trial in patients with her2 and hr early breast cancer
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer